# SEQUOIA (pancreatic cancer)

Source: https://onco.cc/trials/sequoia-pancreatic/  
OnCo record `sequoia-pancreatic` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SEQUOIA added the immune cytokine pegilodecakin to second-line FOLFOX chemotherapy for pancreatic cancer and found no gain in survival, progression or response, another negative test of immunotherapy in this cold tumour.

## Summary

SEQUOIA randomised 567 patients between March 2017 and September 2019 (283 to pegilodecakin plus FOLFOX, 284 to FOLFOX), 94.7 percent of whom had received gemcitabine plus nab-paclitaxel. Median overall survival was 5.8 against 6.3 months (hazard ratio 1.045, 95 percent confidence interval 0.863 to 1.265), progression-free survival 2.1 months in both arms and response 4.6 against 5.6 percent. Thrombocytopenia (55 against 20 percent) and anaemia (40 against 16) were commoner with the cytokine while interleukin-18, interferon gamma and granzyme B rose as expected. Five UK sites took part (Addenbrooke's, Hammersmith, Velindre, University College London Hospitals, Guy's and St Thomas'). The FOLFOX control arm's 6.3 months is a useful benchmark for second-line chemotherapy in the gemcitabine-nab-paclitaxel era.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-24
- Also known as: SEQUOIA pegilodecakin; AM0010 phase 3
- Registry id: NCT02923921
- Phase: 3
- Setting: Metastatic pancreatic ductal adenocarcinoma progressing after one gemcitabine-containing regimen at sites in 13 countries: FOLFOX with or without pegilodecakin, with overall survival as the primary endpoint
- Sponsor: Eli Lilly (ARMO BioSciences)
- Enrolled: 567
- Result: Median overall survival 5.8 months with pegilodecakin plus FOLFOX against 6.3 months with FOLFOX (hazard ratio 1.045, 95 percent confidence interval 0.863 to 1.265); progression-free survival 2.1 months in both arms.
- Outcomes: Overall survival: Pegilodecakin + FOLFOX 5.8 months vs FOLFOX 6.3 months, HR 1.045

## Notes

- UK sites (registry, 5): Addenbrooke's Hospital Cambridge; Hammersmith Hospital; Velindre Hospital Cardiff; University College London Hospitals; Guy's and St Thomas'.

## Sources

- ClinicalTrials.gov NCT02923921: https://clinicaltrials.gov/study/NCT02923921
- Hecht et al., SEQUOIA (JCO 2021): https://doi.org/10.1200/JCO.20.02232

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Pegilodecakin](https://onco.cc/drugs/pegilodecakin/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- terms: [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Pancreatic cancer: the failed and stopped programmes and why](https://onco.cc/terms/pancreatic-failed-programmes/)

---
JSON: https://onco.cc/api/v1/entities/sequoia-pancreatic.json